

Supplementary Materials for
**ACTR5 controls CDKN2A and tumor progression in an
INO80-independent manner**

Xiaobao Xu *et al.*

Corresponding author: Chun-Wei Chen, cweichen@coh.org

Sci. Adv. **8**, eadc8911 (2022)
DOI: 10.1126/sciadv.adc8911

The PDF file includes:

Figs. S1 to S11
Tables S1 to S3
Legend for suppl excel data table

Other Supplementary Material for this manuscript includes the following:

Suppl excel data table





fig. S1. Epigenetic CRISPRi library.

(A) Map of the ipUSEPR vector expressing a sgRNA together with a puromycin-resistant gene (PuroR) and a TagRFP fluorescent protein. DCF01 and DCR03 primers for Illumina sequencing are listed. (B) Distribution of individual sgRNA frequencies (reads per million reads; RPMR) in the epigenetic CRISPRi library with 91.4% of sgRNAs passed the QC by exhibiting $\geq 5\%$ of expected frequency. (C-D) Data correlation of individual sgRNAs of the epigenetic CRISPRi library between (C) two replications at day 0, and (D) the average of day 0 and day 24 (n = 3 each timepoint).

A CRISPR interference (CRISPRi) – dCas9-Krab system



B CRISPR knockout (CRISPR-KO) – Cas9 system




fig. S2. Gene silencing efficiency of the CRISPR systems.

The gene silencing efficiency of (A) CRISPR interference (CRISPRi) and (B) CRISPR knockout (CRISPR-KO) systems was measured by an RFP inactivation assay.




fig. S3. RFP flow cytometric growth competition assay.

(A) Schematic outline of the growth competition assay using the RFP expression labeling the sgRNA transduced cells in the pooled cultures. The RFP-positive % were measured in the DAPI-negative (live), singlet cell population of each sample using an Attune NxT flow cytometer with a 96-well autosampler. (B) Growth competition assay of Cas9-expressing HepG2 (HCC), MV411 (AML), MDA-231 (breast cancer), and U87 (GBM) cells transduced with the RFP-labeled sgNTC (green lines; $n = 2$ independent sequences), sgACTR5 (red lines; $n = 4$ independent sequences), and sgPCNA (blue lines; $n = 1$ sequence; PCNA is an essential gene in most cancer types).

Targets (525 genes)
Non-targets (525 genes)





fig. S4. Comparison of the histone modification landscape at the ACTR5-bound and unbound genes. The HepG2 histone modification ChIP-seq data were obtained from ENCODE Consortium (data source: B. Bernstein, BROAD Institute).

A GO analyses of the down-regulated 175 genes in sgiACTR5



B GO analyses of the up-regulated 109 genes in sgiACTR5





fig. S5. Gene ontology analyses of the ACTR5-regulated genes in HepG2 cells.

Gene ontology analyses (g:Profiler) of the down-regulated (A, 175 genes) and up-regulated genes (B, 109 genes) in sgiACTR5 transduced HepG2 cells over the following databases: (1) GO molecular function (GO:MF), (2) GO biological process (GO:BP), (3) GO cellular component (GO:CC), (4) Kyoto Encyclopedia of Genes and Genomes (KEGG), (5) Reactome (REAC), (6) Human Protein Atlas (HPA), (7) CORUM, and (8) Human Phenotype (HP).

A GO analyses of the down-regulated 175 genes in *sgiACTR5*



B GO analyses of the up-regulated 109 genes in *sgiACTR5*




fig. S6. TRANSFAC analyses of the ACTR5-regulated genes in HepG2 cells.

Gene ontology analyses (g:Profiler) of the down-regulated (A, 175 genes) and up-regulated genes (B, 109 genes) in *sgiACTR5* transduced HepG2 cells over the TRANSFAC database (TF; a database on transcription factors and their DNA-binding sites).





fig. S7. Validation of the CRISPR hypersensitive elements identified by CRISPR tiling scan.

(A) Schematic outline of the CRISPR hypersensitive elements (A1 – A6) and a linker region (L) in ACTR5. (B) Growth competition assay of Cas9-expressing HepG2, SNU475, U251, and U87 cells transduced with sgRNAs targeting individual regions of ACTR5 (sgACTR5), a non-essential sequence (sgNTC), and an essential gene (sgPCNA).




fig. S8. Comparison of sgRNAs used in DepMap and CRISPR gene tiling scan.

Two-dimensional annotation of (A) ACTR5 and (B) IES6 sgRNAs used in the DepMap genome-wide CRISPR screen project (blue; 4 sgRNAs) vs. the CRISPR gene tiling scans used in this study (red; 284 sgRNAs for ACTR5 and 90 sgRNAs for IES6). The red lines indicate the smoothed model of the CRISPR scan score derived from individual sgRNAs (dots) screened in HepG2 cells. The median CRISPR scan scores of the positive control (dotted line; defined as -1.0) and negative control (defined as 0.0) sgRNAs are designated.




fig. S9. Differential regulation of canonical INO80 complex-bound and unbound ACTR5 target genes. Cross analysis of ACTR5-TST ChIP-seq targets (525 genes) with the canonical INO80 complex (c-INO80; defined by the previously reported INO80 and YY1 ChIP-seq in HepG2 cells)(50) bound loci revealed 21.1% of ACTR5 targets (111 genes) were not recognized by c-INO80. A higher proportion of these c-INO80-independent ACTR5 target genes (27.0% vs. 14.5% in the c-INO80 bound ACTR5 targets) showed increased expression upon CRISPR knockdown of ACTR5 in HepG2 cells.




fig. S10. Effect of ACTR5-depletion on SNU475 and MV411 cells.

Level of H3K9me2 at the CDKN2A and GAPDH loci in (A) SNU475 and (B) MV411 cells transduced with sglNTC and sglACTR5. (C) Western blot of ACTR5, CDKN2A, CDK6, Rb, p-Rb, E2F1, and β -actin in MV411 cells transduced with sglNTC and sglACTR5. Data are represented as mean \pm SEM. *P < 0.01 by two-sided Student's t-test.




fig. S11. Correlation of the ACTR5-dependency with CDKN2A expression and proliferation index.

Relationships between (A) relative CDKN2A expression (RNA-seq data obtained from the Cancer Cell Line Encyclopedia [CCLE]) and (B) cellular doubling time (obtained from Cellosaurus and ATCC) with the cellular response to ACTR5-depletion (relative RFP% for each cell model summarized from Fig. 1E).

table S1. CRISPRi sgRNA sequences.

| sgRNA_ID | Sequence |
|------------|-----------------------|
| sgINTC_1 | GATTCTAAAACGGATTACCA |
| sgINTC_2 | GGATGATAACTGGTCCGCAG |
| sgiATCR5_1 | GACTGGGTCCGGTGCGGCAC |
| sgiATCR5_2 | GGGCACGGGCGTCGCGGAAC |
| sgiATCR5_3 | GGACGCGCGCTCCAAGATGG |
| sgiATCR5_4 | GTCCAGCACTGGGTCCGGTG |
| sgilES6_1 | GAAGACTCGGAGTGCGATGG |
| sgilES6_2 | GAAGTTCCAAGGCCCGCGCT |
| sgilES6_3 | GCCCCGCGCTGGGAAAAAGGT |
| sgilES6_4 | GATCAAGACGGAAGTAACAG |

table S2. CRISPR-KO sgRNA sequences.

| sgRNA_ID | Sequence |
|-----------|----------------------|
| sgNTC_1 | ATGTCGCCATAAATAAGAAG |
| sgNTC_2 | TGTGCCAGAGTCCTTCGATA |
| sgATCR5_1 | GGACTACAGCTTCCAGCACC |
| sgATCR5_2 | TATTGTGGTAGAAGCTGAAG |
| sgATCR5_3 | TGTTCTTCTCCTATGAGAGA |
| sgATCR5_4 | ATTTTCCAGCCATCTCTCAT |
| sgPCNA | GGACTCGTCCCACGTCTCTT |

table S3. ChIP-qPCR primer sequences.

| Primer_ID | Sequence |
|--------------|---------------------------|
| CDKN2A TSS_F | TCTGTAAAAAGAAATCCGCC |
| CDKN2A TSS_R | ACAAC TAGGAAAGAATAGTTTTGC |
| HBB TSS_F | ATGCAGAGATATTGCTATTGCCTT |
| HBB TSS_R | TGTATCATGCCTCTTTGCACCA |
| GAPDH TSS_F | CTCGAGGAGAAGTTCCCCAAC |
| GAPDH TSS_R | GTCAAGGACGGGGACCCTTA |

Suppl Excel data table

adc8911_Suppl. Excel_seq1_v2.xlsx